NASDAQ:VBLT - Vascular Biogenics Stock Price, Forecast & News

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Vascular Biogenics Ltd (NASDAQ:VBLT) released its quarterly earnings results on Thursday, November, 14th. The biopharmaceutical company reported ($0.14) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.14). The biopharmaceutical company earned $0.08 million during the quarter, compared to analysts' expectations of $0.24 million. Vascular Biogenics had a negative return on equity of 37.19% and a negative net margin of 3,050.43%. View Vascular Biogenics' Earnings History.

Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Vascular Biogenics.

5 brokerages have issued 1-year price objectives for Vascular Biogenics' shares. Their forecasts range from $2.00 to $3.25. On average, they expect Vascular Biogenics' share price to reach $2.75 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price. View Analyst Price Targets for Vascular Biogenics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vascular Biogenics.

Headlines about VBLT stock have been trending negative on Tuesday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vascular Biogenics earned a news impact score of -2.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Vascular Biogenics.

Vascular Biogenics saw a drop in short interest in December. As of December 31st, there was short interest totalling 43,300 shares, a drop of 25.3% from the December 15th total of 58,000 shares. Based on an average daily volume of 64,200 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.2% of the company's shares are sold short. View Vascular Biogenics' Current Options Chain.

Some companies that are related to Vascular Biogenics include IDEAYA Biosciences (IDYA), Athersys (ATHX), Protagonist Therapeutics (PTGX), Bicycle Therapeutics (BCYC), Five Prime Therapeutics (FPRX), Arbutus Biopharma (ABUS), Ovid Therapeutics (OVID), Nature's Sunshine Products (NATR), Aravive (ARAV), Monopar Therapeutics (MNPR), NuCana (NCNA), Fortress Biotech (FBIO), Arcturus Therapeutics (ARCT), Harrow Health (HROW) and Mustang Bio (MBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include Alibaba Group (BABA), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), AEterna Zentaris (AEZS), Synergy Pharmaceuticals (SGYP), vTv Therapeutics (VTVT), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Opko Health (OPK) and Sangamo Therapeutics (SGMO).

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VBLT stock can currently be purchased for approximately $1.43.

Vascular Biogenics has a market capitalization of $51.31 million and generates $580,000.00 in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Vascular Biogenics employs 39 workers across the globe.View Additional Information About Vascular Biogenics.

The official website for Vascular Biogenics is http://www.vblrx.com/.

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]